15
Urinary Tract
77.
Zimmerman RL, Bagley D, Bibbo M.
Utility of the Bart BTA test in detect-
ing upper urinary tract transitional cell
carcinoma.
Urology
1998;51:956-958.
78.
Nasuti JF, Gomella LG, Bibbo M. Utility
of the BTA stat test kit for bladder cancer
screening.
Diag Cytopathol
1999;21:27-29.
79.
Walsh IK, Keane PF, Ishak LM, et al. The
BTA stat test: a tumor marker for the
detection of upper tract transitional cell
carcinoma.
Urology
2001;58:532-535.
80.
Halling KC, King W, Sokolova IA, et
al. A comparison of BTA stat, hemo-
globulin dipstick, telomerase and Vysis
UroVysion assays for the detection of
urothelial carcinoma in urine.
J Urol
2002;167:2001-2006.
81.
Thomas L, Ley H, Marberger M, et al.
Multicenter trial of the quantitative BTA
Trak assay in the detection of bladder
cancer.
Clin Chem
1999;45:472.
82.
Landman J, Chang Y, Kavaler E, et al.
Sensitivity and specificity of NMP-22,
telomerase, and BTA in the detection
of human bladder cancer.
Urology
1998;52:398-420.
83.
Abbate I, D'Introno A, Cardo G, et al.
Comparison of nuclear matrix protein
22 and bladder tumor antigen in urine
of patients with bladder cancer.
Antican-
cer Res
1998;18:3803.
84.
Lahme S, Bichler KH, Feil G, et al. Com-
parison of cytology and nuclear matrix
protein 22 for the detection and follow-
up of bladder cancer.
Urol Int
2001;66:72.
85.
Poulakis V, Witsch U, Vries D, et al. A
comparison of urinary nuclear matrix
protein-22 and bladder tumor antigen
test with voided urine cytology in
detecting and following bladder cancer.
The prognostic value of false-positive
results.
BJU Int
2001;88:692-701.
86.
Eissa S, Swellam M, Sadek M, et al.
Comparative evaluation of the nuclear
matrix protein, fibronectin, urinary
bladder cancer antigen and voided uri-
nary cytology in the detection of blad-
der tumors.
J Urol
2002;168:465-469.
87.
Halling KC, King W, Sokolova IA, et
al. A comparison of cytology and fluo-
rescence in situ hybridization for the
detection of urothelial carcinoma.
J Urol
2000;164:1768-1775.
88.
Placer J, Espinet B, Salido M, et al. Clini-
cal utility of a multiprobe FISH assay in
voided urine specimens for the detec-
tion of bladder cancer and its recur-
rences, compared with urinary cytology.
Eur Urol
2002;42:547-552.
89.
Sarosdy MF, Schellhammer P, Bokinsky
G, et al. Clinical evaluation of a multi-
target fluorescent in situ hybridization
assay for detection of bladder cancer.
J Urol
2002;168:1950-1954.
90.
Lodde M, Mian C, Negri G, et al. Role
of uCyt in the detection and surveil-
lance of urothelial carcinoma.
Urology
2003;61:243-247.
91.
Pfister C, Chautard D, Devonec M, et al.
ImmunoCyt test improves the diagnos-
tic accuracy of urinary cytology: Results
of a French multicenter study.
J Urol
2003;169:921-924.
92.
Kavaler E, Landman J, Chang Y, et al.
Detecting human bladder carcinoma
cell in voided urine samples by assaying
for the presence of telomerase activity.
Cancer
1998;82:708.
93.
Cassel A, Rahat MA, Lahat N, et al. Tel-
omerase activity and cytokeratin 20 as
markers for the detection and follow-up
of transitional cell carcinoma: An unful-
filled promise.
J Urol
2001;166:841.
94.
Nakagawa T, Kanai Y, Saito Y, et al.
Increased DNA methyltransferase 1 pro-
tein expression in human transitional
cell carcinoma of the bladder.
J Urol
2003;170:2463-2466.
95.
Catto JW, Azzouzi AR, Rehman I,
et al. Promoter hypermethylation
is associated with tumor location,
stage, and subsequent progression in
transitional cell carcinoma.
J Clin Oncol
2005;23:2903-2910.
96.
Wang L, Weber D, Deeds D, et al. DNA
methylation profiling distinguishes low
grade papillary urothelial carcinoma
from reactive urothelia in urine.
Mod
Path
2006;19:74.
97.
Pu RT, Laitala LE, Clark DP. Methyla-
tion profiling of urothelial carcinoma
in bladder biopsy and urine.
Acta Cytol
2006;50(5):499-506.
98.
Sanchez-Carbayo M, Socci ND, Lozano
JJ, et al. Gene discovery in bladder
cancer progression using cDNA microar-
rays.
Am J Pathol
2003;163:505-516.
99.
Dyrskjot L, Thykjaer T, Kruhoffer M, et
al. Identifying distinct classes of bladder
carcinoma using microarrays.
Nat Genet
2003;33:90-96.
100. Osman I, Bajorin DF, Sun T-T, et al.
Novel blood biomarkers of human
urinary carcinoma.
Urol Oncol
2006;24(6):562-563.
101. Karam JA, Lotan Y, Karakiewicz PI, et al.
Use of combined apoptosis biomarkers
for prediction of bladder recurrence and
mortality after radical cystectomy.
Lancet
Oncol
2007;8(2):128-136.
102. Munro NP, Cairns DA, Clarke P, et al.
Urinary biomarker profiling in
transitional carcinoma.
Int J Cancer
2006;119(11):2642-2650.
103. Ramakumar S, Bhuijan J, Besse JA, et al.
Comparison of screening methods in
the detection of bladder cancer.
J Urol
1999;161:388-394.
104. Glas AS, Roos D, Deutehom M, et al.
Tumor markers in the diagnosis of
primary bladder cancers. A systematic
review.
J Urol
2003;169:1975-1982.
105. Liou LS. Urothelial cancer biomarkers
for detection and surveillance.
Urology
2006;67:25-33.
106. Bibbo M, Akerman M, Alves VAF, et al.
How technology is reshaping the prac-
tice of non gynecologic cytology.
Acta
Cytol
2007;51:123-152.
107. Yoder BJ, Skacel M, Hedgepath R, et al.
Reflex Uro Vysion testing of bladder
cancer surveillance patients with
equivocal or negative urine cytology.
Am J Clin Pathol
2007;127:295-301.
437
previous page 433 ComprehensiveCytopathology 1104p 2008 read online next page 435 ComprehensiveCytopathology 1104p 2008 read online Home Toggle text on/off